An interventional study of Pacemaker implantation with Left bundle branch area pacing (LBBAP) and Atrioventricular node ablation (AVNA) in Atrial Fibrillation (AF), sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Atrial Fibrillation by Seoul National University Hospital — 6 open to participants now, 7 under way, none of them phase 3. Atrial Fibrillation · Seoul National University Hospital.
Among the 18 studies in Atrial Fibrillation by Seoul National University Hospital, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 16th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 18 studies in Atrial Fibrillation by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 140 across the 12 interventional studies, 150 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
2 of the studies in Atrial Fibrillation by Seoul National University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05507749Seoul National University HospitalCyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring | 2026-12-31 |
| NCT05794386Seoul National University HospitalSCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Atrial Fibrillation by Seoul National University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.
Study duration:
Procedures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet all of the following inclusion criteria 1)-6).
Patients with at least one of the following:
Exclusion:
Patients who meet at least one of the following exclusion criteria 1)-11).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Left bundle branch area pacing combined with atrioventricular node ablation.
Procedure: Pacemaker implantation with Left bundle branch area pacing (LBBAP) · Procedure: Atrioventricular node ablation (AVNA)
Pharmacologic treatment optimized according to guidelines in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.
Drug: Pharmacologic therapy optimized for Atrial Fibrillation management
Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients. The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice.
Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation. Treatment is tailored based on patient tolerance and clinical efficacy.
Change in NT-proBNP concentration (pg/ml) from baseline to 6-month follow-up
Time frame: 6 months after intervention.
Change in NT-proBNP concentration (pg/ml) at 12, and 24 months
Time frame: 12 months and 24 months after intervention.
Change in health-related quality of life measured by 36-item short form survey (SF-36) questionnaire at 6, 12, 24 months
The SF-36 is a 36-item questionnaire that measures health-related quality of life across eight domains, including physical functioning, bodily pain, and mental health. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
Time frame: 6, 12 and 24 months after intervention.
Change in health-related quality of life measured by EuroQol 5-Dimension Questionnaire (EQ-5D) at 6, 12, 24 months
The EuroQol 5-Dimension Questionnaire (EQ-5D) evaluates health-related quality of life using a descriptive system with five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are derived as an index value (range: -0.594 to 1) The value attached to an EQ-5D profile according to a set of weights that reflect, on average, people's preferences about how good or bad the state is. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'
Time frame: 6, 12 and 24 months after intervention.
Change in left ventricular ejection fraction (LV-EF, %) at 6, 12, and 24 months
Time frame: 6, 12 and 24 months after intervention
Change in left ventricular end-diastolic diameter (LVEDD, mm) at 6, 12, and 24 months
Time frame: 6, 12 and 24 months after intervention.
Change in left ventricular end systolic diameter (LVESD, mm) at 6, 12, and 24 months
Time frame: 6, 12 and 24 months after intervention.
Change in New York Heart Association (NYHA) functional class at 6, 12, and 24 months
The NYHA functional classification system assesses the severity of heart failure symptoms on a scale from Class I (best) to Class IV (worst). Changes in functional class will be evaluated at 6, 12, and 24 months after the intervention to determine the impact on patients' physical activity and symptom burden.
Time frame: 6, 12 and 24 months after intervention.
Change in 6 min walk test at 6, 12, and 24 months
Time frame: 6, 12, and 24 months after intervention
Change in cognitive function measured by Montreal Cognitive Assessment (MoCA) score at 6, 12, and 24 months
The Montreal Cognitive Assessment (MoCA) is a widely used cognitive screening tool that assesses various cognitive domains, including memory, attention, language, visuospatial skills, and executive function. The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function. A score of 26 or above is generally considered normal, while lower scores suggest cognitive impairment. Changes in MoCA scores will be evaluated at 6, 12, and 24 months post-intervention.
Time frame: 6, 12 and 24 months after intervention.
Procedure-related complications (tamponade, device infection, re-intervention, pneumothorax, vascular complications, others)
Time frame: 24 months after intervention.
The all-cause mortality at 24 months
Death from any cause during the 24-month follow-up period.
Time frame: 24 months after intervention.
Worsening Heart Failure (HF) at 24 Months
\*Worsening HF with or without hospitalization: symptoms, signs, imaging, and analytical criteria that require unplanned medical attention with an increase of diuretic use, intravenous diuretic therapy
Time frame: 24 months after intervention.
Composite Outcome: Mortality and worsening heart failure (HF) at 24 months
Participants meeting at least one of the criteria: (a) all-cause mortality, (b) worsening heart failure.
Time frame: 24 months after intervention.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →